drugset / Trial / NCT04519671

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

NCT04519671

Phase 1/2 Terminated 25 enrolled Anthony Lembo
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of using adult allogeneic bone marrow derived mesenchymal stem cells (MSCs), to treat people for medically refractory perianal fistulizing Crohn's disease.

Timeline

Start
2020-11-19
Primary completion
2022-07-12
Completion
2022-11-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 7.5e+07 cells Other